The aim of this study is to evaluate whether patients who benefit from a personalized pharmaceutical plan (PPP) during their hospitalization, allowing them to be informed and sensitized, are treated for a shorter period of time with strong opioids with a reduced risk of dependence compared to a management according to the usual modalities in the rheumatology services concerned.

Inclusion Criteria:

• Patient hospitalized in the rheumatology department
• Patient with acute pain in the context of a non-cancerous, non-traumatic, high-energy musculoskeletal pathology
• Patient for whom a prescription of strong opioid derivatives is initiated in rheumatology or patient for whom a prescription of strong opioid derivatives is maintained in rheumatology if the initial prescription has a maximum duration of 30 consecutive days prior to inclusion

Exclusion Criteria:

• Patient with cancer or fibromyalgia already diagnosed at inclusion
• Patient with poor French language skills
• Taking a strong opioid treatment for more than 30 consecutive days prior to inclusion
• Person judged by the prescriber or pharmacist as not autonomous for the management of strong opioid treatment
• Patient already included in the study